Application and preparation method of mesenchymal stem cell exosome carrying or not carrying exogenous miR-122-5p

The bone marrow mesenchymal stem cell exosomes isolated from the bone marrow of mice that carry or do not carry exogenous miR-122-5p are used to treat acute liver failure, and the problems of difficulty in obtaining and low yield in the prior art are solved, and the problem of high acquisition and low yield is achieved. Efficient improvement of liver function and improved survival rate.

CN118948894APending Publication Date: 2024-11-15THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310541184.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-15
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the prior art, the use of mesenchymal stem cell exosomes from healthy young women to treat liver failure has problems such as difficulty in obtaining and low yield. The treatment of fat-derived mesenchymal stem cells carrying miR-122 has large cells, which leads to difficulty in injection. Problems of inappropriate liver microenvironment.

Method used

Bone marrow mesenchymal stem cell exosomes carrying or not carrying exogenous miR-122-5p were isolated from the supernatant of the 3-5 generation mesenchymal stem cell culture medium of mouse bone marrow, and prepared by conventional purification methods. The Kald protein A or LPS/D-GalN model was used for acute liver failure treatment. The exosome size was 50-150 nm, and the surface markers CD63 and TSG101 were expressed, exosome miR-122 carrying exogenous miR-122-5p- High in 5p content, used to prepare therapeutic drugs.

Benefits of technology

It significantly improves liver function in mice, reduces tissue inflammation and congestion, and improves survival rate. It is simple to prepare exosomes and has high yields, proving that miR-122-5p is the main substance for the treatment of liver failure, solving the problems of acquisition and low yields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948894A_ABST
    Figure CN118948894A_ABST
Patent Text Reader

Abstract

The invention discloses application and a preparation method of a mesenchymal stem cell exosome carrying or not carrying exogenous miR-122-5p, and belongs to the technical field of stem cells. The exosome is separated from culture medium supernate of mesenchymal stem cells of the third generation to the fifth generation of the bone marrow of the mouse. The hepatic failure comprises a hepatic failure model caused by concanavalin A injection or a hepatic failure model caused by LPS / D-GalN intraperitoneal injection. The mesenchymal stem cell-derived exosome can treat acute hepatic failure, significantly improve mouse liver functions and tissue inflammation hyperemia, and increase the survival rate of mice. Meanwhile, the exosome is simple to prepare and high in yield. In addition, the patent verifies that the miR-122-5p is highly expressed in the exosome in the patent, and the main substance of the exosome for treating the hepatic failure is the miR-122-5p.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of stem cells, and in particular relates to an application and preparation method of bone marrow mesenchymal stem cell exosomes carrying or not carrying exogenous miR-122-5p. Background Art

[0002] Liver failure is a disease that seriously threatens human survival. The global incidence of acute liver failure is about 1-6 people / 1,000,000. In addition, there are about 257 million chronic HBV carriers worldwide, and about 70 million chronic HBV carriers in my country. The number of end-stage liver diseases (such as HCC or acute-on-chronic liver failure, ACLF) generated by this is very large. Liver transplantation is the most effective means of treating liver failure, but the shortage of liver sources restricts its large-scale use. Even though the treatment methods are becoming more and more diverse, the mortality rate of liver failure is still as high as 30%-70%. Different treatment methods have different defects, and treatments such as artificial liver and hepatocyte transplantation are also facing unprecedented challenges because they cannot make up for problems such as liver cell exhaustion or tissue rejection.

[0003] Mesenchymal stem cells (MSCs) exist in almost all tissues and organs after birth and can be obtained in large quantities. They are slightly less omnipotent than embryonic stem cells and induced pluripotent stem cells and are relatively safer. Traditionally, it is believed that mesenchymal stem cells mainly treat diseases by differentiating into target cells and regulating the immune microenvironment through paracrine. However, subsequent studies have shown that allogeneic transplantation of mesenchymal stem cells is subject to tissue rejection and will be cleared by the host in the short term, and the proportion of them differentiating into target cells in vivo is very small. Therefore, it is speculated that mesenchymal stem cells mainly exert their therapeutic effects through paracrine mechanisms. Exosomes are small vesicles that originate from endocytosis. They are about 50-150nm in diameter and can be secreted by various cell types. Exosomes are rich in proteins, DNA and RNA, especially non-coding RNA. Because exosomes have a biological membrane structure, they are well tolerated in the body and easy to transmit. The "signal molecules" in the vesicles can affect various biological behaviors of cells through paracrine and endocrine pathways, and have been shown to have therapeutic effects in various disease models. miR-122-5p is highly conserved among species and highly expressed in the liver. It is reported that the expression of miR-122-5p in the liver accounts for about 70% of the expression of all miRNAs. The functions of miR-122-5p in the liver are diverse. miR-122-5p has shown powerful functions in regulating the replication of HCV, inhibiting the occurrence of HCC, and maintaining liver homeostasis. This suggests that miR-122-5p has potential value in the treatment of liver diseases.

[0004] A large number of patents for the treatment of liver damage using exosomes or mesenchymal stem cells carrying miR-122 are disclosed in the prior art. For example, the patent with application number CN201610016951.7 discloses the use of exosomes in the preparation of a drug for the treatment of acute liver failure. The exosomes are exosomes secreted by human menstrual blood mesenchymal stem cells, and the exosomes are isolated from the primary culture supernatant of menstrual blood mesenchymal stem cells. Preferably, the exosomes are derived from healthy human bodies, more preferably from healthy young women, such as women aged 16-25, because they are more active. The patent has the following problems: 1. It is difficult to obtain healthy young women, and 2. The yield of the primary culture supernatant is low, resulting in high costs. For example, the patent with application number CN201310390760.3 discloses the use of adipose-derived mesenchymal stem cells carrying miR-122 in the preparation of a liver fibrosis treatment preparation. The adipose-derived mesenchymal stem cells carrying miR-122 have the basic characteristics and differentiation potential of mesenchymal stem cells; the adipose-derived mesenchymal stem cells carrying miR-122 can resist HBV infection of mesenchymal stem cells. The mesenchymal stem cell treatment has the following problems: 1. Mesenchymal stem cells are large, and injection in animal models is prone to cause embolism; 2. The microenvironment of liver damage has changed, which is not suitable for the differentiation and growth of mesenchymal stem cells, affecting the therapeutic effect of mesenchymal stem cells. Summary of the invention

[0005] The embodiment of the present invention provides an application and preparation method of bone marrow mesenchymal stem cell exosomes carrying or not carrying exogenous miR-122-5p, and the scheme is as follows: On the one hand, an embodiment of the present invention provides a use of bone marrow mesenchymal stem cell exosomes carrying or not carrying exogenous miR-122-5p in the preparation of a drug for treating acute liver failure.

[0006] These include a liver failure model caused by concanavalin A injection or a liver failure model caused by LPS / D-GalN intraperitoneal injection.

[0007] Among them, exosomes are separated from the culture supernatant of the 3rd to 5th generation mesenchymal stem cells from the bone marrow of mice and then obtained by conventional purification methods.

[0008] The source of bone marrow mesenchymal stem cell exosomes carrying exogenous miR-122-5p is obtained by transfecting the 3rd to 5th generation bone marrow mesenchymal stem cells of mice with miR-122-5p mimics and separating the culture medium supernatant.

[0009] Among them, the size of the exosomes is 50-150nm, and the average size of the exosomes prepared in this experiment is about 131.4nm. The surface markers CD63 and TSG101 of the exosomes are expressed. Bone marrow mesenchymal stem cell exosomes carrying or not carrying exogenous miR-122-5p highly express miR-122-5p, and the content of miR-122-5p in bone marrow mesenchymal stem cell exosomes carrying exogenous miR-122-5p is higher. This patent proves that miR-122-5p is the main substance for the treatment of liver failure.

[0010] On the other hand, an embodiment of the present invention further provides a pharmaceutical composition, which includes a pharmaceutically acceptable carrier and the aforementioned exosomes, etc. Among them, the dosage form of the pharmaceutical composition can be various common dosage forms; preferably, the dosage form of the pharmaceutical composition is an injection. The pharmaceutically acceptable carrier can include phosphate buffer and / or physiological saline, etc.

[0011] In another aspect, an embodiment of the present invention further provides a method for preparing the aforementioned exosomes, the method comprising: Preparation of S101 mesenchymal stem cells: Obtain mouse femurs and tibias from mice, peel off the muscle tissue attached to the bone surface, cut off the long bone epiphyses, and directly use mesenchymal stem cell culture medium to flush the bone marrow cavity. The bone marrow cavity flushing fluid is placed in a culture dish for culture. The medium is replaced within 24 hours to remove non-adherent cells. The culture medium is completely replaced 2-3 days later. The adherent cells are digested with trypsin 5-8 days later. The cells are subcultured at a subculture ratio of 1:2 to obtain the 3rd to 5th generation mesenchymal stem cells.

[0012] Preparation of S102 exosomes: The supernatant of the 3rd to 5th generation culture medium of mesenchymal stem cells was collected. When the cells grew to a density of 70%-80%, the culture medium was replaced with a mesenchymal stem cell culture medium prepared with exosome-free serum. After culturing for 24 hours, the cell supernatant was collected, centrifuged to remove cells and cell debris, and the cell supernatant was concentrated using an ultrafiltration tube. Exosomes were extracted using the kit method, and the exosome precipitate was dissolved with PBS.

[0013] Furthermore, the method for preparing bone marrow mesenchymal stem cell exosomes carrying exogenous miR-122-5p is as follows: in step S102, Lipofectamine RNAiMAX is used to transfect miR-122-5p mimics in P3-P5 generation mesenchymal stem cells, and then exosomes are obtained using the cell supernatant 48 hours after transfection. For details, please refer to the subsequent process of preparing the encapsulated miR-122-5p inhibitor.

[0014] The exosomes derived from bone marrow mesenchymal stem cells of the present invention can treat acute liver failure, significantly improve liver function and tissue inflammation and congestion in mice, and increase the survival rate of mice. At the same time, the exosomes are simple to prepare and have high yield. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 It is a flow chart of the preparation and validation of mesenchymal stem cells and exosomes and animal experiments; Figure 2 It is the result of flow cytometry detection of the expression of surface molecular markers of mesenchymal stem cells; Figure 3 This is a microscopic picture of mesenchymal stem cells; Figure 4 This is a schematic diagram of the results of Oil Red O staining of mesenchymal stem cells; Figure 5 This is the particle size distribution diagram of exosomes detected by NTA particle size detection; Figure 6 It is the expression detection result of CD63 and TSG101 in exosomes; Figure 7 This is a transmission electron microscopy picture of exosomes; Figure 8 This is the analysis graph of the top five most abundant miRNAs expressed in the qPCR experiment; Fig. 9 The figure is the result of HE staining of liver tissue sections of acute liver failure mice in two drug administration conditions under the concanavalin A model; Fig.10 It is the comparison result of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the serum of acute liver failure mice treated with two kinds of drugs under the concanavalin A model; Fig.11 The results are the comparison of the expression ratios of inflammatory factors γ-IFN, IL-6 and IL-1β in the liver tissue of acute liver failure mice treated with two types of drugs under the Concanavalin A model; Fig.12 The figure is the result of HE staining of liver tissue sections of acute liver failure mice treated with two kinds of drugs under LPS / D-GalN model; Fig.13 This is a graph showing the survival time of mice in the acute liver failure model treated with two medications under the LPS / D-GalN model; Figure 9-13 There were two types of administration: vehicle (equal volume of PBS) group and Exosomes group; Fig.14 It is the comparison result of alanine aminotransferase (ALT) index in the serum of acute liver failure mice treated with four kinds of drugs under the concanavalin A model; Fig.15 The results of HE staining of liver tissue sections of mice with acute liver failure treated with four types of drugs under the Concanavalin A model; Figure 14-15In the experiment, four types of drug administration were: normal group (Normal), model group (Vehicle+ConA), Inhibitor NC group (Inhibitor NC Exosomes+ConA) and miR-122-5p inhibitor group (miR-122inhibitor Exosomes+ConA); among them, the normal group was not treated, the model group was treated with ConA and exosomes with the same volume of PBS, the Inhibitor NC group was treated with ConA and exosomes secreted by mBMMSCs carrying irrelevant miRNA sequences, and the miR-122-5p inhibitor group was treated with ConA and exosomes secreted by mBMMSCs carrying miR-122-5p inhibitor. DETAILED DESCRIPTION

[0016] In order to make the objectives, technical solutions and advantages of the present invention more clear, the present invention will be further described in detail below with reference to the accompanying drawings.

[0017] See also Figure 1 This embodiment discloses a method for preparing exosomes and a verification process, comprising the following steps: (1) Obtaining mesenchymal stem cells from the bone marrow: Obtain the femur and tibia from C57 mice, peel off the muscle tissue attached to the bone surface, cut off the epiphyses of the long bones, and directly use mesenchymal stem cell culture medium (DMEM / F12 culture medium + 10% FBS + 1% double antibody + 1% L-glutamine) to flush the bone marrow cavity. The bone marrow cavity flushing fluid of 3 mice was placed in a 10 cm dish for culture. The medium was replaced within 24 hours to remove non-adherent cells. The culture medium was completely replaced 2-3 days later. After about 7 days, the cells grew to a density of 80-90%. The adherent cells were digested with trypsin and subcultured at a subculture ratio of 1:2. The 3rd to 5th generation mesenchymal stem cells were obtained for later use.

[0018] (2) Identification of mesenchymal stem cells: 2.1: Flow cytometry identification of mesenchymal stem cells: 1*10 6 Mesenchymal cells were added with mouse CD16 / CD32 antibody and blocked at 4℃ for 10 minutes to remove background signals. 3μg of six antibodies coupled with different fluorescent substances, CD29, CD44, CD90, CD105, CD45, and CD34, were added to the cells and mixed evenly. After incubation at 4℃ for 30 minutes in the dark, the cells were washed twice with FACS washing solution to remove unbound antibodies, and resuspended with 200μl FACS solution and measured on the machine. CD29, CD44, CD90, and CD105 were positive, and CD45 and CD34 were negative. The results are as follows Figure 2As shown, CD29, CD44, CD90, and CD105 are positively expressed, and CD45 and CD34 are negatively expressed. Mesenchymal stem cells have high purity, accounting for about 60% of the total cells isolated.

[0019] The morphological characteristics of P3 mesenchymal stem cells were observed under a microscope. Figure 3 As shown, the cells grew in a spindle shape (dashed box, partial magnification on the right) and had local clone formation (area enclosed by dashed lines).

[0020] 2.2: Osteogenic and adipogenic differentiation: P3 mesenchymal stem cells were induced with adipogenic medium for 21 days, the medium was changed every 2-3 days, and the efficiency of adipose tissue formation was detected by Oil Red O staining. Osteogenic induction conditions: P3 mesenchymal stem cells were induced with osteogenic medium for 14 days, the medium was changed every 2-3 days, and the bone formation was observed by staining with Alizarin Red Kit. Figure 4 As shown, the cells are obviously colored and the induction is successful, which proves that mesenchymal stem cells have the ability to differentiate into osteoblasts and adipocytes.

[0021] (3) Preparation of exosomes: The supernatant of the culture medium of mesenchymal stem cells P3-P5 was collected. When the cells grew to a density of 70%-80%, the culture medium was replaced with a mesenchymal stem cell culture medium prepared with exosome-free serum. After culturing for 24 h, the cell supernatant was collected and centrifuged at 3000 g for 10 min to remove cells and cell debris. The cell supernatant was concentrated using a millipore 100KD cut-off ultrafiltration tube. Exosomes were extracted using the ExoQuick-TC (System Biosciences, USA) kit method (extraction reagent volume: culture supernatant volume = 1:5, after slight inversion to mix, incubate at 4°C overnight, and centrifuge at 4°C 1500 g for 30 min). The exosome precipitate was dissolved with an appropriate amount of PBS.

[0022] (4) Identification of exosomes: 4.1: NTA particle size detection, exosomes are diluted in a certain proportion and then the particle size is detected by nanoparticle tracking analyzer. The diameter range of exosomes is: 50-150nm. The test results are as follows Figure 5 As shown, the average diameter of exosomes detected by NTA particle size detection is 131.4nm, which is consistent with the characteristics of exosomes.

[0023] 4.2: Surface marker detection: detect whether the cell surface has one or more of the following markers: CD9, CD63, CD81, CD82 or TSG101.

[0024] The culture supernatant of P3-P5 mesenchymal stem cells was collected and concentrated using a Millipore centrifugal column ultrafiltration tube with a cutoff of 100KD. The obtained cell supernatant was extracted using an SBI exosome extraction kit, and the exosome precipitate was dissolved with an appropriate amount of PBS, diluted with an appropriate amount of PBS, and then the corresponding volume of 5*SDS protein lysis buffer was added to make the final concentration of 10μg / μl. The control group used an equal volume of dissolved cell fragments and precipitates, denatured at 98℃ for 10min, and cooled for WB verification of the expression of TSG101 and CD63 markers. Immunoblotting showed the specific expression of exosome markers TSG101 and CD63, as shown in the results. Figure 6 shown.

[0025] 4.3: Transmission electron microscopy was used to evaluate the exosome vesicle profile and particle size. The process was as follows: (a) 5 μL of exosome sample was added dropwise onto the copper grid and incubated at room temperature for 5 min.

[0026] (b) After incubation, use filter paper to absorb excess liquid on one side.

[0027] (c) Add 5 μL of 1% phosphotungstic acid onto the copper grid and incubate at room temperature for 1 min.

[0028] (d) After incubation, use filter paper to absorb excess liquid on one side.

[0029] (e) Add a drop of deionized water to the copper mesh, quickly rinse off the excess staining solution, dry it at room temperature, and then observe it on the machine.

[0030] The results of observations are as follows Figure 7 As shown, transmission electron microscopy showed that clear vesicle outlines were visible in the exosome samples under the negative staining field of view, and the particle size met the identification standards of exosomes.

[0031] The above characteristics prove that the obtained exosomes meet the characteristics of exosomes.

[0032] (5) Exosome miRNA sequencing After RNA was extracted from P4BMMSC mesenchymal stem cells, a linker sequence was added and PCR amplification was performed to build a library. The miRNA sequencing results showed that miR-122-5p was highly expressed and the expression abundance of let-7 family members was relatively high; specifically, among the top 20 miRNAs in terms of expression abundance, miR-122-5p ranked third. qPCR was then used to verify that among the let-7 family and the top five miRNAs, miR-122-5p had the highest expression abundance. The results are as follows Figure 8As shown, miR-122-5p has the highest expression level among the top five abundant miRNAs and let-7 family in sequencing. At the same time, miR-122-5p plays a very important role in the occurrence and development of liver diseases, and it is speculated that miR-122-5p is a potential active ingredient for therapeutic effects.

[0033] (6) Verification of the effects of exosomes 6.1: Establishment of acute liver failure mouse model: Concanavalin A (15 mg / kg) or 10 μg / kg LPS (lipopolysaccharide) combined with 400 mg / kg D-GalN (D-galactosamine) was injected intraperitoneally. 6 hours after modeling, serum transaminase was measured and liver pathological changes were evaluated by HE staining to determine whether the acute liver failure model was successfully established. After the experiment, mice developed acute liver failure after intraperitoneal injection of Concanavalin A or 10 μg / kg LPS combined with 400 mg / kg D-GalN, proving that the acute liver failure model was successfully established.

[0034] 6.2: Determine the therapeutic effect of mesenchymal stem cell exosomes on ALF mice: Immediately after model establishment, 600 μg / mouse (dissolved in 200 μl PBS) of exosomes were injected into the tail vein. Eye blood was collected 6 hours later, and liver tissue was used for subsequent evaluation of efficacy. The efficacy index evaluation reference: (a) HE staining of liver tissue paraffin sections was performed to detect liver tissue necrosis in the treatment group.

[0035] (b) The expression changes of AST, ALT, etc. in peripheral serum were detected by the Reitman method (for detailed steps, please refer to the company's operating manual).

[0036] (c) ELISA was used to detect the changes in the expression levels of IL-6, IL-1β and γ-IFN in peripheral blood.

[0037] In the ConA model, tissue sections are sliced ​​as Fig. 9 shown. Fig. 9 The results showed that the liver tissue in the model group (Vehicle) was significantly damaged, with large areas of necrosis, liver tissue congestion, obvious infiltration of red blood cells and lymphocytes, disordered liver cord structure, and obvious immune cell infiltration; the exosome treatment group (Exosomes) showed that liver cell necrosis was significantly reduced, and the liver cords were neatly arranged. Fig.10 shown. Fig.10 The results showed that serum transaminases (ALT, AST) in the model group (Vehicle) were abnormally high, while those in the exosome treatment group (Exosomes) decreased significantly. Fig.11 shown. Fig.11The results showed that the inflammatory factors IL-6, γ-IFN and IL-1β were highly expressed in the model group (Vehicle), and the expression levels of inflammatory factors IL-6, γ-IFN and IL-1β in the exosome treatment group (Exosomes) also decreased significantly.

[0038] In summary, in the ConA model, the exosome treatment group (Exosomes) has a significant therapeutic effect on acute liver failure.

[0039] In the LPS / D-GalN model, HE staining was Fig.12 shown. Fig.12 The results showed that the model group (Vehicle) had pathological changes in liver tissue, with obvious congestion in liver tissue, disordered liver cord structure, and obvious immune cell infiltration; the exosomes group showed reduced congestion in liver tissue, with neatly arranged liver cords. Fig.13 As shown, Fig.13 The results showed that the survival rate of the normal group (Normal) reached 100%, the model group (Vehicle) group died around 5 hours, and all died between 6-7 hours. The exosome treatment group (Exosomes) showed a delayed death time, and the survival rate reached 37.5%. That is, in the LPS / D-GalN model, the survival rate of mice in the exosome treatment group (Exosomes) was significantly improved. At the same time, liver HE staining showed that the liver tissue damage in the exosome treatment group was significantly reduced, liver tissue congestion was reduced, and the liver cord structure was neat.

[0040] In summary, in the LPS / D-GalN model, the exosome treatment group (Exosomes) has a significant therapeutic effect on acute liver failure.

[0041] As can be seen from step (6), exosomes (without transfection) have a good therapeutic effect on acute liver failure caused by concanavalin A (ConA) model and LPS / D-GalN model.

[0042] (7) Verification of the effect of miR-122-5p in exosomes From step (5), it can be concluded that exosomes express a large amount of miR-122-5p (which itself has a therapeutic effect on liver damage). The applicant speculates that the main substance of the therapeutic effect of exosomes on liver failure in step (6) is miR-122-5p. The following implementation is specially designed for verification: Exosomes of transfection inhibitor control (Inhibitor NC) and miR-122-5p inhibitor (miR-122-5p) were obtained respectively, and 600 μg / mouse (dissolved in 200 μl PBS) was immediately injected into the tail vein after model establishment. Serum and liver tissue samples were obtained 6 hours later to evaluate the expression of serum transaminases and the degree of liver tissue damage after miR-122-5p intervention.

[0043] Among them, the preparation of mesenchymal stem cell exosomes encapsulating miR-122-5p inhibitor (miR-122-5p inhibitor) and irrelevant miRNA (inhibitorNC) was: 1*10 6 P3-P5 mesenchymal stem cells were plated on a 10 cm dish and adhered to the dish for 24 hours. Inhibitor NC / miR-122-5p inhibitor (final concentration 100 nM) was transfected using Lipofectamine RNAiMAX. DMEM / F12 complete medium without exosome serum was replaced 7 hours after transfection. The culture supernatant was collected 48 hours later. The subsequent steps refer to the wild-type exosome preparation process (step (3)). The transfection process of bone marrow mesenchymal stem cell exosomes carrying exogenous miR-122-5p can refer to the above process.

[0044] The verification results are as follows: Fig.14 The results showed that serum alanine aminotransferase (ALT) was highly expressed in the model group (Vehicle+ConA), Inhibitor NC group (Inhibitor NC Exosomes+ConA) and miR-122-5p inhibitor group (miR-122inhibitorExosomes+ConA), and the level of ALT in the Inhibitor NC group (about 500U / L) was lower than that in the miR-122-5p inhibitor group (about 5200U / L). Fig.15 The results showed that the model group had severe liver necrosis, with flake necrosis and red blood cell infiltration; the InhibitorNC group had significantly alleviated liver damage, with neatly arranged liver cords and reduced red blood cell infiltration; the miR-122-5p inhibitor group had aggravated liver necrosis, with large flake necrosis, significantly more red blood cells and inflammatory cell infiltration than the Inhibitor NC group, and disordered liver cord structure.

[0045] In summary, the above results indicate that the main agent of the therapeutic effect of exosomes on liver failure is miR-122-5p.

[0046] Explanation of the yield of exosomes: The bone marrow lavage fluid isolated from 6 mice was placed in 2 10cm dishes, each dish had 10 ml of culture medium, and when expanded to P3 generation mesenchymal stem cells, about 80 ml of mesenchymal stem cells could be obtained. 30 ml of mesenchymal stem cell culture supernatant could extract 14,000 μg of exosomes, which could be used to treat about 23 mice (600 μg of exosomes were injected into each mouse). From the above results, it can be seen that the yield of exosomes is very high.

[0047] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. Application of bone marrow mesenchymal stem cell exosomes carrying or not carrying exogenous miR-122-5p in the preparation of drugs for the treatment of acute liver failure.

2. The use according to claim 1, characterized in that: The liver failure model includes a liver failure model caused by concanavalin A injection or a liver failure model caused by LPS / D-GalN intraperitoneal injection.

3. The use according to claim 1, characterized in that: The exosomes are isolated from the culture supernatant of mesenchymal stem cells of passages 3-5 from mouse bone marrow.

4. The use according to claim 1, characterized in that: The bone marrow mesenchymal stem cell exosomes carrying exogenous miR-122-5p are obtained by transfecting the 3rd to 5th generation bone marrow mesenchymal stem cells of mice with miR-122-5p mimics and separating the culture medium supernatant.

5. The use according to claim 1, characterized in that: The size of the exosomes is 50-150 nm, their surface markers include CD63 and TSG101, and they highly express miR-122-5p.

6. A pharmaceutical composition, characterized in that Comprising a pharmaceutically acceptable carrier and the exosomes according to claim 1.

7. The pharmaceutical composition according to claim 6, characterized in that The dosage form of the pharmaceutical composition is injection.

8. The method for preparing exosomes according to claim 1, characterized in that: The method comprises: Preparation of S101 mesenchymal stem cells: Obtain mouse femurs and tibias from mice, peel off the muscle tissue attached to the bone surface, cut off the epiphyses of the long bones, and directly use mesenchymal stem cell culture medium to flush the bone marrow cavity. The bone marrow cavity flushing fluid is placed in a culture dish for culture, and the medium is replaced within 24 hours to remove non-adherent cells. The culture medium is completely replaced 2-3 days later. The adherent cells are digested with trypsin 5-8 days later, and the cells are subcultured at a subculture ratio of 1:2 to obtain the 3rd to 5th generation mesenchymal stem cells; Preparation of S102 exosomes: The supernatant of the 3rd to 5th generation culture medium of mesenchymal stem cells was collected. When the cells grew to a density of 70%-80%, the culture medium was replaced with a mesenchymal stem cell culture medium prepared with exosome-free serum. After culturing for 24 hours, the cell supernatant was collected, centrifuged to remove cells and cell debris, and the cell supernatant was concentrated using an ultrafiltration tube. Exosomes were extracted using the kit method, and the exosome precipitate was dissolved with PBS.

9. The preparation method according to claim 8, characterized in that: The method for preparing bone marrow mesenchymal stem cell exosomes carrying exogenous miR-122-5p is as follows: in step S102, Lipofectamine RNAiMAX is used to transfect miR-122-5p mimics in P3-P5 generation mesenchymal stem cells, and then the exosomes are obtained using the cell supernatant 48 hours after transfection.